Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Emerg Microbes Infect. 2022 Dec;11(1):1828-1832. doi: 10.1080/22221751.2022.2099305.
Distinct SARS-CoV-2 Omicron sublineages have evolved showing increased fitness and immune evasion than the original Omicron variant BA.1. Here, we report the neutralization activity of sera from BNT162b2 vaccinated individuals or unimmunized Omicron BA.1-infected individuals against Omicron sublineages and "Deltacron" variant (XD). BNT162b2 post-dose 3 immune sera neutralized USA-WA1/2020, Omicron BA.1-, BA.2-, BA.2.12.1-, BA.3-, BA.4/5-, and XD-spike SARS-CoV-2s with geometric mean titres (GMTs) of 1335, 393, 298, 315, 216, 103, and 301, respectively; thus, BA.4/5 SARS-CoV-2 spike variant showed the highest propensity to evade vaccine neutralization compared to the original Omicron variants BA.1. BA.1-convalescent sera neutralized USA-WA1/2020, BA.1-, BA.2-, BA.2.12.1-, BA.3-, BA.4/5-, and Deltacron-spike SARS-CoV-2s with GMTs of 15, 430, 110, 109, 102, 25, and 284, respectively. The unique mutation F486V in the BA.4/5 spike contributes to the increased evasion of antibody neutralization by sublineage BA.4/5. The low neutralization titres of vaccinated sera or convalescent sera from BA.1 infected individuals against the emerging and rapidly spreading Omicron BA.4/5 variants provide important results for consideration in the selection of an updated vaccine in the current Omicron wave.Trial registration: ClinicalTrials.gov; identifier: NCT04368728.
不同的 SARS-CoV-2 奥密克戎亚谱系已经进化,显示出比原始奥密克戎变异株 BA.1 更高的适应性和免疫逃避能力。在这里,我们报告了 BNT162b2 接种者或未免疫的奥密克戎 BA.1 感染者血清对奥密克戎亚谱系和“德尔塔克戎”(XD)变体的中和活性。BNT162b2 接种 3 剂后的免疫血清中和了 USA-WA1/2020、奥密克戎 BA.1-、BA.2-、BA.2.12.1-、BA.3-、BA.4/5-和 XD-刺突 SARS-CoV-2,几何平均滴度(GMT)分别为 1335、393、298、315、216、103 和 301;因此,与原始奥密克戎变异株 BA.1 相比,BA.4/5 SARS-CoV-2 刺突变体显示出最高的逃避疫苗中和的倾向。BA.1 恢复期血清中和了 USA-WA1/2020、BA.1-、BA.2-、BA.2.12.1-、BA.3-、BA.4/5-和 XD-刺突 SARS-CoV-2,GMT 分别为 15、430、110、109、102、25 和 284。BA.4/5 刺突中的独特突变 F486V 导致亚谱系 BA.4/5 逃避抗体中和的能力增强。接种疫苗血清或 BA.1 感染恢复期血清对新兴和迅速传播的奥密克戎 BA.4/5 变异体的低中和效价为当前奥密克戎浪潮中选择更新疫苗提供了重要结果。
ClinicalTrials.gov;标识符:NCT04368728。